Switch to:
More From Other Websites
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
Can The Uptrend Continue for ChemoCentryx (CCXI)? Dec 15 2014
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% Dec 15 2014
US STOCKS-Oil slump leads Wall St to worst week in 2-1/2 years Dec 12 2014
The rout was on, as major averages post worst weekly loss since 2012 Dec 12 2014
US STOCKS-Oil, materials lead Wall St towards weekly loss Dec 12 2014
US STOCKS-Oil, materials lead Wall St towards weekly loss Dec 12 2014
US STOCKS-Wall St declines as oil tumbles further Dec 12 2014
ChemoCentryx Inc Conference Call to Discuss Top-Line Phase II Results in Patients With Diabetic... Dec 12 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor... Dec 12 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor... Dec 12 2014
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II... Dec 11 2014
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II... Dec 11 2014
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% Dec 08 2014
ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a... Dec 04 2014
ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug... Nov 20 2014
CHEMOCENTRYX, INC. Financials Nov 18 2014
ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
ChemoCentryx to Present at Two Upcoming Investor Conferences Nov 06 2014
ChemoCentryx to Present at Two Upcoming Investor Conferences Nov 06 2014
ChemoCentryx posts 3Q loss Nov 06 2014
ChemoCentryx posts 3Q loss Nov 06 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 05 2014
ChemoCentryx Reports Third Quarter 2014 Financial Results and Provides Corporate Update Nov 05 2014
ChemoCentryx Reports Third Quarter 2014 Financial Results and Provides Corporate Update Nov 05 2014
Q3 2014 ChemoCentryx Inc Earnings Release - After Market Close Nov 05 2014
ChemoCentryx to Hold Third Quarter 2014 Financial Results Conference Call on Wednesday, November 5,... Oct 22 2014
ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective... Oct 21 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease Oct 20 2014
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% Oct 17 2014
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
ChemoCentryx receives orphan status for 5a receptor Jun 02 2014
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head... Mar 27 2014
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013 Mar 13 2014
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday,... Mar 03 2014
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference Feb 25 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK